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Objectives: Norway introduced newborn screening for Cystic Fibrosis (CF) in
March 2012 based on a three tier immunoreactive trypsinogen (IRT)/DNA/DNA
protocol. The cystic ﬁbrosis transmembrane conductance regulator (CFTR) mutation
spectrum of Norwegian CF patients as well as mutations previously not seen in the
population were included in the mutation panels. We present the results from the
ﬁrst 22 months of nationwide CF screening in Norway.
Methods: IRT was measured using GSPTM (Perkin Elmer) and samples above
60 ng/ml were included in 2nd tier testing. This involved Luminex-based analysis
of 71 mutations and Sanger sequencing of a local common mutation. If only one
mutation was found, 3rd tier testing included sequencing of an additional panel
of clinically rare alleles found in Norwegian CF patients. Infants carrying two
mutations were reported for diagnostic follow-up.
Results: At the end of 2013, 111 648 samples had been screened for CF and
875 children (0.78%) had tested positive in primary IRT screening. 2nd tier
DNA assessments revealed 22 samples carrying two CFTR mutations. 3rd tier
DNA testing of 86 samples disclosed one child with two mutations. Based on
the 23 reported children the most frequent alleles were p.R117H (32.6%) and
p.F508del (30.4%). In addition, ﬁve infants where no mutation was found were
reported due to very high IRT values (>400 ng/ml).
Conclusion: We found fewer children with a clear CF genotype than expected,
and the CFTR mutations and allele frequencies were different compared to clinical
material. This suggests reviewing the IRT cut-off level and continued reporting of
p.R117H variants as well as extending the 2nd tier mutation panel.
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Background: ECFS guidelines include nPD if diagnostic tests for CF are inconclu-
sive. Equations have been derived that may accurately differentiate CF from non-CF
[Wilschanski (eqW)1 and Sermet (eqS)2]. Retrospectively, we analysed nPD traces
from our Difﬁcult CF Diagnosis (DCFD) Service to examine agreement between
the two equations and with the clinician’s interpretation (CI).
Methods: 66 patients underwent nPD testing at a median (range) age of
18.5 (2−67) yrs. nPD traces were also analysed from healthy controls (HC, n = 6) and
DF508/DF508 CF patients (n = 10). Proportions of agreement (PA) were calculated.
Results: For HC and DF508/DF508 there was perfect agreement (PA= 1) between
all 3 analysis methods. In DCFD patients, CI of nPD results in the context of
history/investigations led to the following categories: (a) Non-CF : n = 44 (68.2%).
eqS was concordant with CI (PA= 1); eqW led to 2 subjects being classiﬁed as
CF (PA= 0.95); neither has an identiﬁed CFTR mutation; (b) Variant/atypical CF :
n = 9 (13.6%): 6 were labelled CF by eqS (PA= 0.67) and 3 with eqW (PA= 0.33).
Agreement between the two equations was poor (PA= 0.5). On extended CFTR
analysis, 2 patients have no CFTR mutations, 1 has one and 6 have two.
Conclusions: Both equations work well in classical CF patients and in HC. They
were also highly concordant with each other, and CI, in patients referred to the
DCFD clinic in whom CF was ruled out. Agreement was poor between the equations
in more complex patients with possible variant CF or with traces considered
equivocal or adversely affected by inﬂammation. nPD may be most robust at ruling
out CF, particularly as full CFTR gene sequencing becomes more readily available.
